Pharmocann
Medical Cannabis Cultivation and R&D
Company Overview
Snapshot
Founded in April 2008, Pharmocann operates with 1–10 employees. The company has raised $690K across one funding round and went public on TASE in December 2018.
Business overview
Pharmocann is a Health Tech & Life Sciences company focused on the development and production of medical cannabis. Operating in the Pharma & Medical Biotechnology and Ag Tech sectors, the company cultivates medical cannabis in Jezreel Valley, Israel, utilizing hothouses for growth, propagation, and R&D of various strains. Pharmocann also develops medical marijuana cultivation centers and dispensaries, and through strategic partnerships, produces standardized, GMP-manufactured medical cannabis products including oils, ointments, tablets, inhalers, suppositories, and pre-rolled cigarettes. The company serves over 3,000 patients monthly and produces approximately two tons of medical cannabis annually, with recent developments including hydrogel products for painful diseases, acute dermatological conditions, and inflammatory bowel diseases.
Strategic signal
In November 2021, Pharmocann partnered with Shamir Institute to explore the use of magic mushrooms, signaling a strategic diversification beyond traditional cannabis products into emerging areas of psychedelic medicine. This collaboration indicates the company's intent to broaden its research and development pipeline and potentially tap into new therapeutic markets, offering investors a view into its long-term growth strategy within the broader health and life sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- When did Pharmocann go public?
- Pharmocann went public on TASE in December 2018.
- What was a significant partnership for Pharmocann in 2021?
- In November 2021, Pharmocann teamed up with Shamir Institute to research magic mushrooms, indicating an expansion into new therapeutic areas.
- What was the latest development regarding Pharmocann's production capacity?
- In April 2022, Pharmocann announced an expansion of its production capacity.
- What was a notable event concerning Pharmocann's cannabis production in July 2022?
- In July 2022, a fungus infiltrated Pharmocann's cannabis crops, leading to the unexpected departure of the CEO.
- What was the outcome of Pharmocann's stock offering in September 2022?
- In September 2022, Pharmocann issued shares at end-of-season prices, resulting in a 27% drop in its stock.